Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Inder Chaudhary"'
Autor:
Irwin Hollander, Aranapakam Venkatesan, Semiramis Ayral-Kaloustian, Osvaldo dos Santos, Zecheng Chen, Efren Delos Santos, Christoph Dehnhardt, Inder Chaudhary, Judy Lucas, Larry R. Feldberg, Robert Mallon
Purpose: The aim of this study was to show preclinical efficacy and clinical development potential of PKI-587, a dual phosphoinositide 3-kinase (PI3K)/mTOR inhibitor.Experimental Design: In vitro class 1 PI3K enzyme and human tumor cell growth inhibi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66371ba1c25913d233d6894b0d41e8b5
https://doi.org/10.1158/1078-0432.c.6518286.v1
https://doi.org/10.1158/1078-0432.c.6518286.v1
Autor:
Irwin Hollander, Aranapakam Venkatesan, Semiramis Ayral-Kaloustian, Osvaldo dos Santos, Zecheng Chen, Efren Delos Santos, Christoph Dehnhardt, Inder Chaudhary, Judy Lucas, Larry R. Feldberg, Robert Mallon
Supplementary Figures S1-S10; Supplementary Tables S1-S5.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ed5c97961b902ade92d28cf1ef4eddb
https://doi.org/10.1158/1078-0432.22441143
https://doi.org/10.1158/1078-0432.22441143
Publikováno v:
Pediatric Drugs. 22:561-570
This was a single-dose, one-period, multicenter, pharmacokinetic (PK) study to evaluate the PK of methylphenidate (MPH) hydrochloride multilayer extended-release capsules (MPH-MLR) in preschool children aged 4 to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dec0dd7587bae80785ce5d60da59e22d
https://doi.org/10.1007/s40272-020-00409-z
https://doi.org/10.1007/s40272-020-00409-z
Publikováno v:
Paediatric Drugs
Objective This was a single-dose, one-period, multicenter, pharmacokinetic (PK) study to evaluate the PK of methylphenidate (MPH) hydrochloride multilayer extended-release capsules (MPH-MLR) in preschool children aged 4 to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::687e099f3c3c99919b91f92f5d65d753
https://pubmed.ncbi.nlm.nih.gov/32776159
https://pubmed.ncbi.nlm.nih.gov/32776159
Autor:
Yutian Zhan, Xinkang Wang, Giora Z. Feuerstein, Bin-Bing S. Zhou, Inder Chaudhary, Lei Zhao, Robert T. Abraham, John Alvarez
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 339:421-429
The mammalian target of rapamycin (mTOR) has proven to be a valid therapeutic target in a number of human cancers, and it is a candidate for clinical trials in human breast cancer. We report on a biomarker-based translational medicine approach to ass
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c9b3038c1d9622ed6929a15dced1c63
https://doi.org/10.1124/jpet.111.185249
https://doi.org/10.1124/jpet.111.185249
Autor:
Rasmy Talaat, JoAnn Scatina, Abdul E. Mutlib, Robert Espina, Zecheng Chen, Inder Chaudhary, Tarek S. Mansour, Aranapakam Mudumbai Venkatesan, Christoph Martin Dehnhardt, Kathlene Babalola, Karthick Vishwanathan
Publikováno v:
Drug Metabolism and Disposition. 39:106-116
It is important to gain an understanding of the pharmacological activities of metabolite(s) of compounds in development, especially if they are found in systemic circulation in humans. Pharmacological evaluation of metabolites is normally conducted w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41c4f366b5028e6c30eb4b77c0652ff2
https://doi.org/10.1124/dmd.110.032490
https://doi.org/10.1124/dmd.110.032490
Autor:
Frank Boschelli, Judy Lucas, Daniel Wang, Erick Honores, Inder Chaudhary, Diane H. Boschelli, Jennifer M. Golas, Yan Wang, Biqi Wu, Ana Carolina Barrios Sosa
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 20:2924-2927
The 7-alkene-3-quinolinecarbonitrile 20, a potent inhibitor of Src enzymatic and cellular activity with IC50 values of 2.1 and 58 nM, respectively, had comparable efficacy to bosutinib in a colon tumor xenograft study.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1f894ee0202ec1e293be393b3575b38
https://doi.org/10.1016/j.bmcl.2010.03.025
https://doi.org/10.1016/j.bmcl.2010.03.025
Autor:
Aranapakam Mudumbai Venkatesan, Christoph Martin Dehnhardt, Osvaldo Dos Santos, Larry Feldberg, Gulnaz Khafizova, Judy Lucas, Robert Mallon, Natasja Brooijmans, Robert T. Abraham, Zecheng Chen, Inder Chaudhary, James Joseph Gibbons, Ker Yu, Efren Guillermo Delos Santos, Tarek S. Mansour, Irwin Hollander, Semiramis Ayral-Kaloustian
Publikováno v:
Journal of Medicinal Chemistry. 53:2636-2645
The PI3K/Akt signaling pathway is a key pathway in cell proliferation, growth, survival, protein synthesis, and glucose metabolism. It has been recognized recently that inhibiting this pathway might provide a viable therapy for cancer. A series of bi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4be4949f3e973bf8cd0b293f9dc47ab0
https://doi.org/10.1021/jm901830p
https://doi.org/10.1021/jm901830p
Autor:
Osvaldo Dos Santos, Inder Chaudhary, Kim Arndt, Judy Lucas, Veronica Diesl, Natasja Brooijmans, Aranapakam Mudumbai Venkatesan, Semiramis Ayral-Kaloustian, Kevin J. Curran, Max Follettie, Susan Quinn Dejoy, Lei Chen, Efren Guillermo Delos Santos, Christoph Martin Dehnhardt, Zecheng Chen, Rosanne Petersen, Tarek S. Mansour, Yi Geng
Publikováno v:
Journal of Medicinal Chemistry. 53:897-910
We are introducing a novel series of 2,4-diaminoquinazolines as beta-catenin/Tcf4 inhibitors which were identified by ligand-based design. Here we elucidate the SAR of this series and explain how we were able to improve key molecular properties such
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71e05daac3bd05bde9e23c93510e3ae1
https://doi.org/10.1021/jm901370m
https://doi.org/10.1021/jm901370m
Autor:
Robert Mallon, Semiramis Ayral-Kaloustian, Irwin Hollander, Zecheng Chen, Judy Lucas, Aranapakam Mudumbai Venkatesan, Tarek S. Mansour, Christoph Martin Dehnhardt, Ker Yu, Natasja Brooijmans, Efren Guillermo Delos Santos, Inder Chaudhary, Jay Gibbons, Osvaldo Dos Santos, Larry Feldberg, Robert T. Abraham
Publikováno v:
Journal of Medicinal Chemistry. 53:798-810
Herein we describe the identification and lead optimization of triazolopyrimidines as a novel class of potent dual PI3K/mTOR inhibitors, resulting in the discovery of 3 (PKI-402). Compound 3 exhibits good physical properties and PK parameters, low na
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d276d951cd1ddfc627844bd76e54113a
https://doi.org/10.1021/jm9014982
https://doi.org/10.1021/jm9014982